SEC Form 4 · accession 0001781450-26-000002
Protalix BioTherapeutics, Inc. · PLX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dror Bashan
Officer — PRESIDENT AND CEO · Director
Period of report
Sep 3, 2026
Accepted (ET)
Sep 4, 2026 · 6:00 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001006281
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F1 | $2.59 | Sep 3, 2026 | A | 320,000 | A | — | Sep 3, 2036 | Common Stock | 320,000 | 320,000 | D |
| Restricted Stock UnitsF3,F4 | — | Sep 3, 2026 | A | 160,000 | A | — | — | Common Stock | 160,000 | 160,000 | D |
Explanation of responses
- F1The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan.
- F2Does not include (i) options to purchase 160,000 shares of common stock at an exercise price equal to $4.69 per share that expire on June 30, 2029, (ii) options to purchase 750,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 340,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.
- F3Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.
- F4The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.